Entries by Maren Kühr

Sustainable, automated, ULT storage

The volume of samples and drug products requiring -80°C storage continues to increase, and shows no sign of slowing down. For many organisations, meeting these growing ULT ­storage ­requirements is challenging. The sheer volume of samples necessitates extensive storage capacity, which demands significant space, substantial energy use, and intensive management. Centralising and automating sample storage can provide a comprehensive solution.

Pichia protein production

Recombinant protein production in Pichia typically relies on AOX1 ­promoter-driven expression using methanol for induction. However, some companies avoid methanol due to safety concerns or operational demands. VALIDOGEN’s unique AOX1 promoter variants enable methanol-free protein production at high space-time yields, offering advantages beyond safety. Latest case studies underscore the strength of this technology.

Focus on long-term protection

Multiple sclerosis is currently an incurable, chronic autoimmune disease. While it is possible to effectively manage the feared relapses with existing therapies, novel approaches aim to provide important protection against long-term impairments.

Ensuring sustainability and continuity in biomanufacturing

Biomanufacturers must balance the development of new therapeutic modalities and reduce manufacturing costs while maintaining environmental responsibility. Efforts are centred on improving process robustness and efficiency and creating more flexible manufacturing facilities that can accommodate diverse biopharmaceutical products.

Well Prepared to Tackle New Pandemics

If you want to successfully guard against future pandemics, you’re going to need a good plan – and the right kind of vaccine producers. WACKER and CordenPharma have been commissioned by the German government to prepare their mRNA vaccine production lines for a new pandemic.

Your mRNA Partner in Europe

Messenger RNA (mRNA) has gained significant attention since being used in the Pfizer-BioNTech and Moderna COVID-19 vaccines. mRNA holds potential for preventing and treating many difficult-to-treat or genetic diseases, including cancers. However, its production is complex and raises challenges for researchers developing new therapies: Discover Tebubio.

A “Pure Play” Biologics Swiss-based CDMO

The biologics contract development and manufacturing (CDMO) market is experiencing rapid growth and is dominated by global players with investments in large scale stainless steel capacity.
But is larger always better? Not necessarily says Celonic, a mid-sized, privately owned CDMO, who has been embracing next generation technologies to help small to large biotech customers bring their drugs reliably, effectively and efficiently to the market.

The West’s wake-up call to China’s biotech dominance

The U.S. House of Representatives recently passed the BIOSECURE Act, prohibiting U.S. biopharma companies from working with Chinese contractors due to national security concerns, including data leaks and intellectual property theft. The Act is expected to pass the Senate.